Background. The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-associated tuberculous meningitis is unknown.
recommend initiation of ART between 2 and 8 weeks in patients presenting with HIV infection and tuberculosis.
Tuberculous meningitis (TBM) is the most severe form of tuberculosis, killing or disabling more than half of those affected [4] . HIV-associated TBM has a similar clinical presentation [5] [6] [7] but higher mortality [8, 9] . The management of TBM is problematic because early initiation of ART may be complicated by a central nervous system (CNS) IRIS, leading to neurological deterioration or death. Thus, the optimal time to initiate ART may differ for TBM compared with that for extracranial tuberculosis. We conducted a randomized, controlled trial of immediate versus deferred initiation of ART in patients with HIV infection and TBM, to determine whether immediate ART reduced the risk of death.
METHODS

Study Design
The study was a randomized, double-blind, placebo-controlled trial with 2 parallel arms: immediate ART (initiated within 7 d of commencing tuberculosis treatment) and deferred ART (initiated after 2 months of tuberculosis treatment).
Sample Size Calculation
The case-fatality rate for patients with HIV-associated TBM in 2 previous studies was 65% [8, 9] . We calculated that 222 patients would be required to provide at least 80% power to detect a 30% reduction in mortality at 9 months from 65% to 45.5%, with a 2-sided significance level of 5%. In order to allow for a 10% loss to follow-up we aimed to recruit 247 patients.
Study Participants and Laboratory Investigations
Study participants were recruited at Pham Ngoc Thach Hospital and the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. Cerebrospinal fluid (CSF) specimens were stained and cultured by standard methods for pyogenic bacteria, fungi, and mycobacteria. Isolates of Mycobacterium tuberculosis were tested for susceptibility to first-line agents. All patients were tested for antibodies to HIV and hepatitis C virus (HCV) and for hepatitis B virus (HBV) surface antigen. CD4 cell counts were performed by flow cytometry (FACSCalibur; Becton Dickinson). Plasma HIV RNA loads were determined using the Abbott RealTime HIV-1 assay (Abbott Laboratories).
Inclusion and Exclusion Criteria
Patients were eligible for the trial if they were aged R15 years and HIV infected and fulfilled diagnostic criteria for TBM, as described elsewhere [9] . Patients were categorized as having definite, probable, or possible TBM. Patients were classified as having definite TBM if the CSF specimen was smear positive for acid-fast bacilli and/or culture positive for M. tuberculosis. Patients were classified as having probable TBM if they fulfilled 1 of 4 criteria: chest radiograph consistent with pulmonary tuberculosis, other specimens (eg, sputum, lymph node, or gastric washings) that were positive for acid-fast bacilli, evidence of extrapulmonary tuberculosis, or radiological features of TBM on computed tomographic or magnetic resonance imaging scan. Patients were classified as having possible TBM if they fulfilled 2 of 4 criteria (past history of tuberculosis, illness duration of .5 days, Glasgow coma score (GCS) of ,15, or focal neurological signs) and 2 of 3 further criteria (yellow CSF, .50% of lymphocytes in the CSF, or CSF glucose level ,50% of the blood glucose level).
TBM disease severity was assessed using the modified Medical Research Council (MRC) TBM grade, as described elsewhere [4] . Grade I TBM was defined as a GCS of 15 with no focal neurology, grade II TBM as a GCS of 15 with a focal neurological deficit or a GCS of 11-14, and grade III TBM as a GCS of %10.
Patients were ineligible for the trial if they had 1 or more of the following exclusion criteria: positive CSF Gram or India ink stain; known or suspected pregnancy; antituberculosis treatment 8-30 d immediately prior to recruitment; previous ART; laboratory contraindications to ART or antituberculosis therapy (hemoglobin level of ,7.0 g/dL, blood neutrophil count of ,. 
Consent Procedures
Written informed consent was obtained from the patient or a relative if the patient could not provide consent. For unconscious patients with no available relatives, the consent of 2 independent physicians was considered acceptable. Patients who recovered consciousness reconsented to the study.
Randomization Procedures
Stratified variable block randomization according to modified MRC TBM grade at presentation was used to assign participants to the 2 treatment groups. Antiretroviral or placebo tablets were placed in coded, sealed boxes; drug appearance and administration schedules were identical to maintain blinding among attending physicians and nurses.
Treatments
In adults previously untreated for tuberculosis, initial therapy was with oral isoniazid at a dose of 5 mg/kg (maximum dose, 300 mg/d), rifampicin at a dose of 10 mg/kg (maximum dose, 600 mg/d), pyrazinamide at a dose of 25 mg/kg (maximum dose, 2 g/d), and ethambutol at a dose of 20 mg/kg (maximum dose, 1.2 g/d), once daily for 3 months. After 3 months, pyrazinamide and ethambutol were stopped and the patient continued treatment with rifampicin and isoniazid at the same doses for another 6 months. Intramuscular streptomycin (dose, 20 mg/kg; maximum dose, 1g/d) was added to the initial treatment regimen of patients previously treated for tuberculosis. Second-line antituberculosis therapy was unavailable during the study. Unless it was contraindicated, all patients received dexamethasone at an initial dose of .3-.4 mg/kg/d, according to modified MRC TBM grade at presentation, and tapered over 6-8 weeks, as described elsewhere [4] . Antiretroviral or placebo tablets were commenced as soon as possible after randomization. The antiretroviral regimen was oral zidovudine (GlaxoSmithKline) at a dose of 300 mg twice daily, lamivudine (GlaxoSmithKline) at a dose of 150 mg twice daily (as a fixed-dose combination tablet), and efavirenz (Merck) at a dose of 800 mg once daily (if taken with rifampicin) or efavirenz at a dose of 600 mg once daily (if taken without rifampicin). Placebos were manufactured by GlaxoSmithKline (zidovudine and lamivudine placebo) and Brecon Pharmaceuticals (efavirenz placebo). After 2 months, all patients received antiretroviral drugs until the end of the study period (12 months).
All patients with a baseline CD4 cell count of ,200 cells/lL received oral co-trimoxazole at a dose of 960 mg daily after 4 weeks [10] .
Medications were administered orally or via nasogastric tube. Patients received directly observed therapy during their inpatient stay (up to 3 months); administration was supervised by family members after hospital discharge.
Patient Monitoring
The study physicians reviewed inpatients daily and completed a weekly standard assessment. As outpatients, participants were assessed monthly until 9 months and at 12 months after randomization.
Routine laboratory tests were monitored weekly for inpatients and monthly for outpatients. CD4 cell counts and plasma HIV-1 RNA levels were measured 3 times each month. CSF samples were taken at baseline and at 1, 2, 3, 6, 9, and 12 months.
Outcome Assessment
The primary outcome was the time from randomization to death in the first 9 months of follow-up. Patients who did not die were censored at the time they were last known to be alive or at 9 months, whichever was earlier.
Secondary outcome measures were time to death during the 12-month follow-up period, HIV-related outcomes (CD4 cell count response, HIV-1 RNA load response, and time to new or recurrent AIDS-defining illness or death), and other secondary outcomes, including time to fever clearance (defined as a maximum daily temperature of ,37.5°C for at least 6 consecutive days), time to coma clearance (GCS of 15 for at least 3 consecutive days), time to first neurological event (defined as any neurological deterioration, coma, seizures, cranial nerve palsy, hemiplegia, paraplegia, cerebellar symptoms or cerebral herniation, or decrease in GCS of R2 points from the highest previously recorded score for at least 2 d or for 1 d plus subsequent death) or death, any grade 3 or 4 adverse event, and neurological disability. Adverse events were graded using the Division of AIDS Table for Grading of Severity of Adult and Paediatric Adverse events. Neurological disability was assessed using the 2 simple questions and modified Rankin scale and classified as good, intermediate, severe disability, or death, as described elsewhere [4] .
Study Oversight
The trial was approved by the hospitals' institutional review boards and the Oxford Tropical Research Ethics Committee. A Data and Safety Monitoring Committee oversaw conduct of the trial and reviewed adverse event and mortality data after 20 deaths, then after 6, 12, and 18 months of recruitment, and at the end of recruitment. The trial was not stopped early.
Statistical Analysis
The primary endpoint was compared between the groups by means of the log-rank test and visualized with Kaplan-Meier curves. The analysis was repeated in prespecified subgroups (TBM disease grade, TBM diagnostic category, CD4 cell count at baseline, and HIV-1 RNA load at baseline) and in the perprotocol population. The per-protocol population excluded major protocol violators and patients who withdrew consent or were lost to follow-up. The primary endpoint was also analyzed with a Cox regression analysis adjusted for the following baseline variables: TBM disease grade, CD4 cell count, HIV-1 RNA load, hemoglobin level, and serum sodium level.
Analyses of time to new or recurrent AIDS event or death, and time to first neurological event or death, were perfomed as for the primary endpoint. The cumulative incidence functions of patients achieving HIV-1 RNA suppression, fever clearance, or coma clearance were compared between the 2 arms using the Fine and Gray regression model [11] , taking into account the competing risk of prior death. We compared CD4 cell count change from baseline at months 2 and 12 in survivors by use of the Mann-Whitney U test. The number of patients with adverse events in each arm was compared using the Fisher exact test. Disability scores at month 12 were compared using a linear trend test.
Multiple imputation was used to account for missing baseline variables and missing follow-up HIV RNA load, CD4 cell count, and disability status measurements. All adjusted regression analyses were based on imputed data.
All analyses were performed with the statistical software R (version 2.8.1; R Foundation for Statistical Computing) [13] and the contributed R packages MICE (for multiple imputation) and cmprsk (for competing risk analyses).
RESULTS
There were 703 patients screened between 20 September 2005 and 28 December 2007 ( Figure 1) ; 253 participants were randomly assigned to immediate ART (127 patients) or deferred ART (126 patients), and 38 patients (19 in each group) were excluded after randomization from the per-protocol analysis (Figure 1) .
Twenty-eight patients withdrew or were lost to follow-up after a median of 82 days (interquartile range, 24-158 days). The distribution of age, sex, disability status, GCS, TBM grade, CD4 cell count, and HIV-1 RNA load at baseline was similar to that in patients who remained in the study.
Baseline Characteristics
Patient characteristics at randomization were similar in the 2 treatment arms (Table 1) . Study participants were predominantly young, male, and intravenous drug users. The median baseline CD4 cell count was 41 cells/lL, and the median baseline plasma HIV-1 RNA level was 5.4 log 10 copies/mL. 
Primary Endpoint
In the first 9 months after randomization, 76 patients in the immediate ART group and 70 in the deferred ART group died (hazard ratio [HR] of immediate versus deferred ART, 1.12; 95% confidence interval [CI], .81-1.55; P 5 .50). The majority of deaths (45 in the immediate ART group and 40 in the deferred ART group) occurred within the first month. The results of the per-protocol analysis were similar to those of the intention-to-treat analysis. There was no evidence for heterogeneity of the treatment effect in any of the prespecified subgroups (Table 2 and Figure 2) .
Immediate ART was not associated with improved 9-month survival (HR, 1.17; 95% CI, .85-1.63; P 5 .34) in the multiple Cox regression analysis. Baseline TBM disease grade was a strong independent predictor for death (HR for TBM grade II, 1.66; 95% CI, 1.07-2.57; P 5 .02 compared with TBM grade I; HR for TBM grade III, 3.42; 95% CI, 2.29-5.33; P , .001 compared with TBM grade I). Other baseline variables such as CD4 cell Only 1 death in each arm occurred between 9 and 12 months of follow-up, and 12-month survival results were virtually identical to the those of the primary analysis (HR, 1.12; 95% CI, .81-1.54; P 5 .50).
Adverse Events
There was a high frequency of severe (grade 3 or 4) adverse events in the immediate and deferred ART groups (368 and 318, respectively) ( Table 3) . Significantly more patients in the immediate ART group experienced grade 4 adverse events (102 vs 87, respectively; P 5 .04). Immediate ART was also associated with a higher frequency of patients with grade 3 and 4 adverse events (109 vs 95, respectively; P 5 .04) and grade 4 adverse events (77 vs 59, respectively; P 5 .03) during the first 2 months.
Thirty-one patients in each group developed a new or recurrent AIDS event; there was no evidence of an association between treatment arm and time to AIDS or death (P 5 .31) ( Table 3) . Fifty-one (40%) and 50 (40%) patients in the immediate and deferred ART groups, respectively, experienced a neurological event (Table 3) ; there was no significant association with the treatment arm (P 5 .54) ( Table 3 ). There were no significant differences in laboratory adverse events, although hepatitis occurred more frequently in the immediate ART arm (Table 3) .
Secondary Outcome Measures
Secondary outcome measures are summarized in Table 4 . The CD4 cell count response at 2 months was higher, and the time to virological suppression was faster, in the immediate ART group. There was no significant difference in CD4 count response at 12 months, and of the 38 patients with documented plasma HIV RNA at 12 months, only 2 (5%, both in the immediate ART group) had a detectable measurement.
DISCUSSION
Currently there is limited evidence to guide the decision when to initiate ART in HIV-infected patients presenting with tuberculosis. Observational studies have suggested that initiation of ART during tuberculosis therapy improves outcome in patients with HIV infection and tuberculosis [14] [15] [16] [17] [18] [19] . Clinical trials to determine optimal timing of initiation of ART in HIV and tuberculosis coinfection are currently underway [20] , and three randomized controlled trials have reported preliminary data [21, 22] . A South African study of patients with pulmonary tuberculosis has reported a reduction in mortality rate among patients receiving ART during tuberculosis treatment, compared with those who receive ART after completion of tuberculosis treatment [21] . Preliminary data from three studies addressing the optimal time to initiate ART during TB therapy in patients with predominantly pulmonary TB have yielded conflicting results. A Cambodian study [22] showed improved survival among patients randomised to early (2 weeks) versus deferred (8 weeks) ART. In contrast, a South African study [23] and an international study [24] failed to demonstrate a reduction in AIDS and death with early ART, apart from in patients with a baseline CD4 count ,50 cells/mm 3 . Of note, IRIS occurred more frequently in the early ART arm.
In contrast to these three trials, we found no association between immediate ART and improved survival in patients with HIV-associated TBM; moreover, the confidence interval for the hazard ratio associated with immediate ART treatment was sufficiently narrow to exclude a risk reduction of R20% due to immediate ART. Furthermore, immediate ART appeared to be associated with a higher frequency of severe (grade 4) adverse events, suggesting that early ART initiation may actually be detrimental in this group. It was not possible to determine which component of the ART regimen was responsible for this increase. Interestingly, there was no significant increase in neurological events in the immediate ART group, which might have been anticipated had this excess been caused by efavirenz or a CNS IRIS. Neurological deterioration often occurred suddenly, and it was rarely possible to perform investigations in order to establish the cause. Potential causes include paradoxical reactions (in patients not receiving ART), CNS IRIS, another CNS opportunistic infection, or drug-resistant tuberculosis. Multidrug-resistant tuberculosis was uncommon in our study, accounting for only 4% of M. tuberculosis isolates. One factor that may have attenuated the effects of TBM IRIS on mortality in the immediate ART group was the use of adjunctive corticosteroids; this may have masked excess mortality.
The most common laboratory adverse event was severe hepatitis, defined as a serum transaminase level .5 times the ULN, which occurred in 20% patients. Although hepatitis appeared to be more common in the immediate ART group, this was not statistically significant. The high rate of hepatitis may have been related to drug toxicities and/or coinfection with HBV and HCV, which was common in the Vietnamese population and more frequent in the immediate ART group. There was no association between treatment group and interruption of antituberculosis or antiretroviral therapy. Severe anemia was also a common adverse event in both groups, but there was no significant difference between groups.
We acknowledge several limitations of our study. The primary endpoint was all-cause mortality at 9 months; we were unable to distinguish deaths related to tuberculosis or HIV infection from other causes of death. Our study included all patients who fulfilled clinical diagnostic criteria for TBM; however, culture confirmation rates were high, and there was no significant difference in outcome between patients who had definite TBM and those who had probable or possible TBM. TBM is the most severe form of tuberculosis, and mortality is associated with disease severity at presentation. If this is compounded by profound immunosuppression related to advanced HIV infection, the beneficial effects of ART may not occur quickly enough to alter early TBM-related mortality. As discussed above, preliminary data from three trials involving patients with predominantly pulmonary TB have yielded conflicting results. One Cambodian study suggested was [22] . In contrast, two further studies, also in patients with predominantly pulmonary tuberculosis, have reported preliminary data [23] [24] . Both showed no reduction in AIDS or death with immediate ART, apart from in patients with a baseline CD4 count ,50 cells/mm 3 . Of note IRIS occurred more frequently in the immediate ART arm. Elsewhere, a study of immediate versus deferred ART in HIVassociated cryptococcal meningitis suggests that early ART is detrimental in the setting [25] . Thus, the optimal time to initiate ART in CNS tuberculosis may well differ from that in extracranial tuberculosis. Finally, our study population included a high proportion of intravenous drug users, who are often coinfected with viral hepatitis; this may limit the generalizability of our findings to other populations. In summary, our study provides evidence that immediate ART does not improve mortality in patients presenting with HIV-associated TBM. Indeed, the overall mortality among patients with HIV-associated TBM who were treated with ART was surprisingly similar to that among historical patients who did not receive ART during tuberculosis treatment. Immediate ART appeared to be associated with an increase in the frequency of grade 4 adverse events, suggesting that it may be safer to defer initiation of ART in patients presenting with HIV-associated TBM. Our findings emphasize the need for early diagnosis and treatment of HIV infection, before patients present with advanced disease and life threatening opportunistic infections such as TBM. The Wellcome Trust, UK, funded the study and had no role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the paper for publication.
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